Y Innovations Welcomes Ipsita Roymoulik, PhD and Georgia Mitsi, PhD, MBA
March 06, 2024
Y Innovations Group is pleased to welcome Massachusetts-based Ipsita Roymoulik, PhD and Georgia Mitsi, PhD, MBA as partners in the company’s Advisory and Consulting unit. Dr. Roymoulik will lead the CMC, Quality, and Compliance Department and Dr. Mitsi will sit in the Business and Competitive Strategy Department.
“We are thrilled to welcome Dr. Roymoulik and Dr. Mitsi to Y Innovations. With their deep knowledge in handling complex matters for a wide range of biotechnology and health technology companies, Dr. Roymoulik and Dr. Mitsi will be immediate assets in advising our clients,” said Megan Yung, Chief Executive Officer of Y Innovations Group.
Dr. Roymoulik brings 22 years of CMC, Quality, and Compliance expertise supporting clinical development of oligonucleotide, RNA and cell therapy drugs. Dr. Roymoulik holds a PhD in Chemical Biology from the University of Michigan, an M.S. in Organic Chemistry from the Indian Institute of Technology Kanpur, and a B.S. in Chemistry from Presidency University.
“I am thrilled to join Y Innovations, an advocate in the current reinvention of the drug development industry. Y Innovations provides an exciting opportunity to broadly serve the industry and I am looking forward to bringing my in-depth CMC, Quality, and Compliance experience across multiple therapeutic modalities and platform technologies to this role,” said Ipsita Roymoulik, PhD.
In her new capacity at Y Innovations, Dr. Roymoulik will be leading the CMC, Quality, and Compliance Department, consulting on a wide range of complex matters in which she has previously led teams at drug innovators and contract manufacturers, including analytical development, process development, manufacturing, supply chain, quality control and quality assurance.
Prior to joining Y Innovations, Dr. Roymoulik worked at SQZ Biotechnologies Company as the Senior Vice President of CMC & Quality. During her tenure, Dr. Roymoulik enabled adoption of rapid technologies to yield high cell therapy manufacturability (100%), full release of cell therapy product in 5-days and administration of 60+ batches of autologous product across 20 domestic/international clinical sites for 3 programs. Previously, Dr. Roymoulik served as the Director of Analytical Development at Moderna Therapeutics where she pioneered platform CMC approaches for the first 10 INDs and additionally initiated quality control and quality assurance functions for the company. Dr. Roymoulik also supported and advised multiple clients on cutting-edge analytical technologies for over a decade at Nitto Denko Avecia, the world’s leading cGMP Oligonucleotide CDMO. For her contributions to the field, Dr. Roymoulik was a 2021 GV Impact List honoree, out of 300+ GV portfolio submissions, for making a difference to her company’s culture, innovation and growth.
Dr. Mitsi brings 20 years of experience in the pharmaceutical industry in a variety of roles ranging from scientific research to business development with a focus on digital health and new, innovative technologies. Dr. Mitsi holds a B.S in Biology from the University of Patras, a PhD in Pharmaco-epidemiology and an M.S in Applied Clinical Sciences from the School of Medicine at the University of Patras, and an MBA from the University of Miami.
“I am excited to join Y Innovations and work alongside professionals who are agents of change. I have devoted my career to digital healthcare and research to improve on the traditional methods since 2012 and am very passionate about helping companies achieve the next level of innovation,” said Dr. Mitsi.
As a partner in our Business and Competitive Strategy Department, Dr. Mitsi will consult on a variety of different aspects, including corporate strategy, pipeline development, fundraising strategy, and business development and large collaborations.
Prior to joining Y Innovations, Dr. Mitsi was an early adopter and advocate for the use of artificial intelligence technologies in healthcare. She was the Founder and CEO of Apptomics, a successful digital healthcare company. Dr. Mitsi also previously held executive leadership positions in Sunovion Pharmaceuticals as an Executive Director in the Frontier Business unit and at Biogen as their General Manager for the Mental Health and VR Solutions department.
Dr. Mitsi is a true advocate for advancing knowledge in the scientific field and has been the keynote speaker in a variety of healthcare conferences such as HIMSS, CNS Summit, DHV-NET: Therapeutic use of VR, BioFuture-2021-2023, SXSW- 2021, and Health 2.0-Japan 2019, among many others. She has also been recognized by CenterWatch as a Top 20 innovator and selected by PharmaVoice 100 in 2018 as one of the most influential people in healthcare. She will be receiving an Outstanding Leadership Award at Health 2.0, in March 2024.
About Y Innovations Group
The Y Innovations Group combines strategic consulting, start-up incubation, and funding under one roof. Our clients and Innovations benefit from our world-class consulting services and leverage our extensive network for funding and corporate growth opportunities. Y Innovations Group works with companies across the biotechnology and pharmaceutical, energy, and AI industries, including large public and private companies as well as early-stage companies.
Media Inquiries: info@y-innovations.com
